SEATTLE--(BUSINESS WIRE)--Aug. 15, 2017--
Omeros Corporation (NASDAQ: OMER), a commercial-stage biopharmaceutical
company committed to discovering, developing and commercializing
small-molecule and protein therapeutics for large-market as well as
orphan indications targeting inflammation, complement-mediated diseases
and disorders of the central nervous system, announced today the pricing
of its previously announced underwritten public offering of 3,000,000
shares of its common stock at a price to the public of $22.75 per share,
before deducting underwriting discounts and other estimated offering
expenses. This bought deal offering is expected to close on or about
August 18, 2017, subject to the satisfaction of customary closing
conditions. In addition, Omeros has granted the underwriters a 30-day
option to purchase up to 450,000 additional shares of its common stock.
Cantor Fitzgerald & Co. is acting as the sole bookrunner for the
offering. H.C. Wainwright & Co. is acting as lead manager and
JonesTrading Institutional Services LLC and Maxim Group LLC are acting
as co-managers in the offering.
Omeros intends to use the net proceeds of the offering for general
corporate purposes, including expenses related to funding research and
development for its OMS721 programs and clinical trials, pre-clinical
studies, manufacturing and other costs associated with advancing its
product candidates toward Biologic License Application and New Drug
Application submissions. Omeros may also use the net proceeds for
working capital, the repayment of debt obligations, acquisitions or
investments in businesses, products or technologies that are
complementary to its own, and other capital expenditures.
A registration statement on Form S-3 (File No. 333-219959) relating to
the securities was filed with the Securities and Exchange Commission on
August 14, 2017. The securities may be offered only by means of a
prospectus, including a prospectus supplement, forming a part of the
effective registration statement. A preliminary prospectus supplement
and accompanying prospectus were filed with the Securities and Exchange
Commission on August 14, 2017. An electronic copy of the preliminary
prospectus supplement and accompanying prospectus relating to the
offering will be available on the website of the Securities and Exchange
Commission at www.sec.gov.
Copies of the final prospectus supplement and accompanying prospectus
relating to the offering may be obtained, when available, by contacting
Cantor Fitzgerald & Co., Attn: Capital Markets, 499 Park Ave., 5th
Floor, New York, New York 10022, or by telephone at 212-829-7122, or by
e-mail at prospectus@cantor.com.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy any securities of Omeros, and shall not
constitute an offer, solicitation or sale of any security in any state
or jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the securities
laws of any such state or jurisdiction.
About Omeros Corporation
Omeros is a commercial stage biopharmaceutical company committed to
discovering, developing and commercializing both small-molecule and
protein therapeutics for large-market as well as orphan indications
targeting inflammation, complement-mediated diseases and disorders of
the central nervous system.
Forward-looking Statements
This press release contains “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933 and Section 21E of
the Securities Exchange Act of 1934, which are subject to the “safe
harbor” created by those sections for such statements. All statements
other than statements of historical facts are forward-looking
statements. Terms such as “anticipate,” “believe,” “could,” “estimate,”
“expect,” “goal,” “intend,” “may,” “plan,” “potential,” “predict,”
“project,” “should,” “will,” “would” and similar expressions and
variations thereof are intended to identify forward-looking statements,
but these terms are not the exclusive means of identifying such
statements. Forward-looking statements are based on management’s beliefs
and assumptions and on information available to management only as of
the date of this press release. Omeros’ actual results could differ
materially from those anticipated in these forward-looking statements
for many reasons, including, without limitation, risks associated with
product commercialization and commercial operations, unproven
preclinical and clinical development activities, regulatory oversight,
intellectual property claims, competitive developments, litigation, and
the risks, uncertainties and other factors described under the heading
“Risk Factors” in the company’s most recent Quarterly Report on Form
10-Q and Annual Report on Form 10-K filed with the Securities and
Exchange Commission. Given these risks, uncertainties and other factors,
you should not place undue reliance on these forward-looking statements,
and the company assumes no obligation to update these forward-looking
statements, even if new information becomes available in the future.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170815005592/en/
Source: Omeros Corporation
Cook Williams Communications, Inc.
Jennifer Cook Williams
Investor
and Media Relations
360.668.3701
jennifer@cwcomm.org
